Clinical trials: Metabolic Evaluation
Bone Metabolism
Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.
The purpose of this study is to evaluate the effect of pioglitazone on bone metabolism in postmenopausal women with impaired fasting glucose.
- Trial name
- NCT00708175
- Testing
- Pioglitazone
- Where
- 34 sites in United States
- Volunteers
- 156 people
- Sponsor
- Takeda
Type 2 Diabetes
Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2
A Randomized, Double-blind, Multi-center, Placebo-controlled, Phase III Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2 Add-on to Metformin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin…
- Trial name
- NCT07076056
- Testing
- DW1026C1, DW1026C2, DW1026S
- Where
- South Korea
- Volunteers
- 230 people
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Crigler-Najjar Syndrome
Gene Transfer Clinical Study in Crigler-Najjar Syndrome
This is a Phase 1/2, multinational, open-label, ascending-dose, delayed-treatment concurrent control clinical study to evaluate the safety and preliminary efficacy of AT342 in subjects with Crigler-Najjar aged ≥1 year.
- Trial name
- VALENS (NCT03223194)
- Testing
- AT342
- Where
- 4 sites in United States, Israel and 1 more
- Volunteers
- 1 people
- Sponsor
- Audentes Therapeutics
Diabetes Mellitus, Non-Insulin-Dependent
Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus
This is a multicenter, randomized, blinded, placebo-controlled, short-term, dose-response study to examine the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes.
- Trial name
- NCT00044694
- Testing
- AC2993 2.5 mcg
- Where
- 33 sites in United States
- Volunteers
- 156 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects
To evaluate the efficacy and dose-response relationship of HRS9531 injection versus placebo in controlling blood glucose after 20 weeks of treatment in subjects with type 2 diabetes who have suboptimal glycaemic control after…
- Trial name
- NCT05966272
- Testing
- HRS9531 injection
- Where
- China
- Volunteers
- 199 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Primary Open-Angle Glaucoma (POAG)
MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)
Hypothesis: The use of neurocytoprotectors helps restore the functional activity of mitochondria, improve the nervous activity of the retina and optic nerve, and stabilize the glaucomatous process.
- Trial name
- NCT06437639
- Testing
- Mexidol
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- Pharmasoft
Obesity
A Study to Evaluate ALN-6222 in Participants With Obesity
This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222…
- Trial name
- NCT07624071
- Testing
- ALN-6222
- Where
- Canada
- Volunteers
- 88 people
- Sponsor
- Alnylam Pharmaceuticals
Metabolic Syndrome X
Study In Patients With Dyslipidaemia
Study in patients with dyslipidaemia.
- Trial name
- NCT00264667
- Testing
- GW677954
- Where
- 50 sites in Argentina, Australia and 11 more
- Volunteers
- 290 people
- Sponsor
- GlaxoSmithKline
Metabolic Syndrome X
Evaluation of the Effects of a L.Reuteri Strain on Markers of Inflammation, Cardiovascular Risk and Fatty Liver Disease
The purpose of this study is the evaluation of the effects in obese patients with metabolic syndrome on the composition of the intestinal microbiota, markers of the syndrome (hypertension, dyslipidemia, inflammation biomarkers…
- Trial name
- PROSIR (NCT02972567)
- Testing
- Lactobacillus spp, Control
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Biosearch S.A.
Dehydration
Biomarkers for Noninvasive Assessment of Human Hydration
Low levels of dehydration (the loss of body water corresponding to 2% of the body weight), deteriorate physical and cognitive performance and may also be linked to a number of chronic diseases.
- Trial name
- NCT01507129
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Gaia Medical Institute
Diabetes Mellitus, Non-Insulin-Dependent
Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes
BMS-820132 is an investigational new drug being developed by BMS for treating Type 2 diabetes. The purpose of this study is to test the safety/tolerability (potential side effects) of single doses of the investigational new drug…
- Trial name
- NCT01105429
- Testing
- BMS-820132
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Bristol-Myers Squibb
Hypercholesterolemia, Lipid Metabolism Disorders
Metabolic Effects of an Ophiocordyceps Sinensis- and CoQ10-Based Formulation in Mild-to-Moderate Hypercholesterolemia
This randomized, double-blind, placebo-controlled study will evaluate the metabolic effects of CORDICOL, a formulation containing Ophiocordyceps sinensis extract (200 mg) and Coenzyme Q10 (50 mg), in adults with mild-to-moderate…
- Conditions
- Hypercholesterolemia, Lipid Metabolism Disorders, Lipid Metabolism, Nutraceutical
- Trial name
- CORDICOL (NCT07852481)
- Testing
- CORDICOL
- Volunteers
- 140 people
- Sponsor
- noiVita Srls
Diabetes Mellitus, Type 2, Obesity
A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 Diabetes
A new study medicine called NNC0519-0130 to improve treatment options for people living with excess body weight, with or without type 2 diabetes.
- Trial name
- NCT06567041
- Testing
- NNC0519-0130
- Where
- Germany
- Volunteers
- 82 people
- Sponsor
- Novo Nordisk A/S
Osteoporosis
CONFIRM - Study of AGN1 LOEP in Patients With Osteoporosis
The study will evaluate the immediate procedure and post-procedure profile of the AGN1 Femoral LOEP™ Kit. All subjects will receive the treatment and be evaluated for any adverse or serious adverse events that could occur during…
- Trial name
- NCT02916953
- Testing
- AGN1 Femoral Local Osteo-Enhancement Procedure
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 60 people
- Sponsor
- AgNovos Healthcare, LLC
Diabetes, Diabetes Mellitus, Type 1
Observational Study on Levemir® in Obese Diabetic Patients
This study is conducted in Europe. The aim of this observational study is to investigate the effect of switch from other basal insulin treatments to Levemir® on body weight in obese diabetic patients.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- KILOS (NCT00849342)
- Testing
- insulin detemir
- Where
- 2 sites in Netherlands, Slovenia
- Volunteers
- 580 people
- Sponsor
- Novo Nordisk A/S
Hypercholesterolemia
Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)
The purpose of this 24 week study is to compare the effectiveness and safety of different doses of Niacin ER/Simvastatin (NS) in subjects with elevated fat levels in their blood (dyslipidemia).
- Trial name
- NCT00080275
- Testing
- Niacin Extended-Release and simvastatin Tablets
- Volunteers
- 600 people
- Sponsor
- Kos Pharmaceuticals
Dyslipidemias
A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia
The purpose of this two-part study is to evaluate the safety and tolerability of the study drug known as LY3202328 in healthy overweight participants in Part A, and those with dyslipidemia (abnormal blood fats) in Part B.
- Trial name
- NCT02714569
- Testing
- LY3202328, Atorvastatin, Simvastatin
- Where
- 4 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity, Behavior, Health
Evaluation of Brain Activity Changes After a Behavior Change Weight Loss Intervention
The aim of this study is to compare brain changes in individuals with overweight or obesity enrolled in either the Noom Healthy Weight program or a matched control.
- Conditions
- Obesity, Behavior, Health, Weight Loss
- Trial name
- NCT04522245
- Testing
- Noom Healthy Weight; mobile behavior change program for weight loss., Matched Control
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Noom Inc.
Diabetes Mellitus, Type 2
Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers
This is a an open-label, randomized, single dose, four-way crossover, multi-stage study enrolling 20 healthy adult male and female subjects per part.
- Trial name
- NCT01725672
- Testing
- Metformin, 500 mg extended release tablet, Metformin, 1000 mg extended release tablet, Glimepiride, 1 mg immediate release tablet
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Overweight
WS®1442 in Slightly Overweight Subjects
The purpose of this study is to test: 1. Safety of 900 mg or 1800 mg of WS® 1442 per day in overweight subjects (BMI 25 to 29,9 kg/m²) 2.
- Trial name
- NCT00982501
- Testing
- WS® 1442 900 mg/d, WS® 1442 1800 mg/d, Nordic walking training 2 x 30 min/week
- Where
- Austria
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Dr. Willmar Schwabe GmbH & Co. KG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.